Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-18
2010-10-26
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S416000
Reexamination Certificate
active
07820711
ABSTRACT:
Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.
REFERENCES:
patent: 6358992 (2002-03-01), Pamukcu et al.
patent: 6875598 (2005-04-01), Buggy et al.
patent: 7220774 (2007-05-01), Albert
patent: 2004/0157930 (2004-08-01), Mascagni
patent: 2005/0080249 (2005-04-01), Buggy
patent: 2007/0281934 (2007-12-01), Buggy et al.
patent: WO-2004-061101 (2004-07-01), None
patent: WO-2004-089293 (2004-10-01), None
patent: WO-2004-110418 (2004-12-01), None
Laport, G. G. et al., “Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation,” Blood 102(6):2004-2013 (2003).
Porter et al., “A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation,” Blood 107(4):1325-1331 (2006).
Rapoport, A.P. et al., “Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer,” Nat. Med. 11(11):1230-1237 (2005).
Schultz, B.E. et al., “Kinetics and Comparative Reactivity of Human Class I and Class IIb Histone Deacetylases,” Biochemistry 43(34):11083-11091 (2004).
Somoza, J.R. et al., “Structural Snapshots of Human HDAC8 Provide Insights Into the Class I Histone Deacetylases,” Structure 12(7):1325-1334 (2004).
Won, J. and Kim, T.K., “Histone Modifications and Transcription Factor Binding on Chromatin: ChIP-PCR Assays,” Methods Mol. Biol. 325:273-283 (2006).
PCT/US07/73802 Search Report dated Mar. 20, 2008.
PCT/US07/84718 Search Report dated Mar. 31, 2008.
Balasubramanian Sriram
Buggy Joseph J.
Henley, III Raymond J
Pharmacyclics Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Uses of selective inhibitors of HDAC8 for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of selective inhibitors of HDAC8 for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of selective inhibitors of HDAC8 for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166184